Growth hormone therapy for hypopituitary adults: Time for re-appraisal

Ariel L. Barkan, David R. Clemmons, Mark E. Molitch, Paul M. Stewart, William Francis Young

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The advent of the production of large quantities of recombinant growth hormone (GH) has made it possible to have sufficient material to assess its efficacy in adult growth hormone deficiency (GHD). Although some studies have shown that patients who are severely deficient benefit from GH therapy, the spectrum of GHD is broad, and the degree of deficiency at times is very difficult to define. In some cases, benefit is not easily quantified, and some studies have claimed benefits that, although statistically significant, are either not clinically important or are so marginal as to be questionable in terms of cost, difficulty of administration and potential risks. The purpose here is to identify the current problems in the diagnosis of GHD, to discuss the rationale for GH therapy and to assess the potential effects of GHD as well as the benefits of GH therapy in GHD adults. We will include a commentary as to which effects appear more robust than others and which are likely to result in the greatest patient benefit. Finally, some attention will be paid to long-term safety issues that should be monitored to ensure that this medication is safe even for the patients with the greatest need.

Original languageEnglish (US)
Pages (from-to)238-245
Number of pages8
JournalTrends in Endocrinology and Metabolism
Volume11
Issue number6
DOIs
StatePublished - Aug 1 2000

Fingerprint

Growth Hormone
Therapeutics
Safety
Costs and Cost Analysis

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Growth hormone therapy for hypopituitary adults : Time for re-appraisal. / Barkan, Ariel L.; Clemmons, David R.; Molitch, Mark E.; Stewart, Paul M.; Young, William Francis.

In: Trends in Endocrinology and Metabolism, Vol. 11, No. 6, 01.08.2000, p. 238-245.

Research output: Contribution to journalArticle

Barkan, Ariel L. ; Clemmons, David R. ; Molitch, Mark E. ; Stewart, Paul M. ; Young, William Francis. / Growth hormone therapy for hypopituitary adults : Time for re-appraisal. In: Trends in Endocrinology and Metabolism. 2000 ; Vol. 11, No. 6. pp. 238-245.
@article{3c99b7a838fd4e10b126cbedaedd79d7,
title = "Growth hormone therapy for hypopituitary adults: Time for re-appraisal",
abstract = "The advent of the production of large quantities of recombinant growth hormone (GH) has made it possible to have sufficient material to assess its efficacy in adult growth hormone deficiency (GHD). Although some studies have shown that patients who are severely deficient benefit from GH therapy, the spectrum of GHD is broad, and the degree of deficiency at times is very difficult to define. In some cases, benefit is not easily quantified, and some studies have claimed benefits that, although statistically significant, are either not clinically important or are so marginal as to be questionable in terms of cost, difficulty of administration and potential risks. The purpose here is to identify the current problems in the diagnosis of GHD, to discuss the rationale for GH therapy and to assess the potential effects of GHD as well as the benefits of GH therapy in GHD adults. We will include a commentary as to which effects appear more robust than others and which are likely to result in the greatest patient benefit. Finally, some attention will be paid to long-term safety issues that should be monitored to ensure that this medication is safe even for the patients with the greatest need.",
author = "Barkan, {Ariel L.} and Clemmons, {David R.} and Molitch, {Mark E.} and Stewart, {Paul M.} and Young, {William Francis}",
year = "2000",
month = "8",
day = "1",
doi = "10.1016/S1043-2760(00)00267-8",
language = "English (US)",
volume = "11",
pages = "238--245",
journal = "Trends in Endocrinology and Metabolism",
issn = "1043-2760",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Growth hormone therapy for hypopituitary adults

T2 - Time for re-appraisal

AU - Barkan, Ariel L.

AU - Clemmons, David R.

AU - Molitch, Mark E.

AU - Stewart, Paul M.

AU - Young, William Francis

PY - 2000/8/1

Y1 - 2000/8/1

N2 - The advent of the production of large quantities of recombinant growth hormone (GH) has made it possible to have sufficient material to assess its efficacy in adult growth hormone deficiency (GHD). Although some studies have shown that patients who are severely deficient benefit from GH therapy, the spectrum of GHD is broad, and the degree of deficiency at times is very difficult to define. In some cases, benefit is not easily quantified, and some studies have claimed benefits that, although statistically significant, are either not clinically important or are so marginal as to be questionable in terms of cost, difficulty of administration and potential risks. The purpose here is to identify the current problems in the diagnosis of GHD, to discuss the rationale for GH therapy and to assess the potential effects of GHD as well as the benefits of GH therapy in GHD adults. We will include a commentary as to which effects appear more robust than others and which are likely to result in the greatest patient benefit. Finally, some attention will be paid to long-term safety issues that should be monitored to ensure that this medication is safe even for the patients with the greatest need.

AB - The advent of the production of large quantities of recombinant growth hormone (GH) has made it possible to have sufficient material to assess its efficacy in adult growth hormone deficiency (GHD). Although some studies have shown that patients who are severely deficient benefit from GH therapy, the spectrum of GHD is broad, and the degree of deficiency at times is very difficult to define. In some cases, benefit is not easily quantified, and some studies have claimed benefits that, although statistically significant, are either not clinically important or are so marginal as to be questionable in terms of cost, difficulty of administration and potential risks. The purpose here is to identify the current problems in the diagnosis of GHD, to discuss the rationale for GH therapy and to assess the potential effects of GHD as well as the benefits of GH therapy in GHD adults. We will include a commentary as to which effects appear more robust than others and which are likely to result in the greatest patient benefit. Finally, some attention will be paid to long-term safety issues that should be monitored to ensure that this medication is safe even for the patients with the greatest need.

UR - http://www.scopus.com/inward/record.url?scp=0033861244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033861244&partnerID=8YFLogxK

U2 - 10.1016/S1043-2760(00)00267-8

DO - 10.1016/S1043-2760(00)00267-8

M3 - Article

C2 - 10878755

AN - SCOPUS:0033861244

VL - 11

SP - 238

EP - 245

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

SN - 1043-2760

IS - 6

ER -